Why Synergy Pharmaceuticals Rallied 12% Today

Synergy Pharmaceuticals (NASDAQ: SGYP) updated investors on the performance of its chronic idiopathic constipation (CIC) drug, Trulance, at the Ladenburg Thalmann Healthcare Conference on Sept. 26 and the Cantor Fitzgerald global healthcare conference on Sept. 27. Its message appears to have resonated with investors, since shares in Synergy Pharmaceuticals finished 12% higher on Friday.

Industry watchers have previously said they expect Trulance revenue of around $21 million this year. Based on Synergy Pharmaceuticals' investor presentations this week, Trulance's fast-growing prescription volume could have it on track to hit that target.

IMAGE SOURCE: GETTY IMAGES.

Source: Fool.com